Table II.
Association between characteristics and prognosis of patients with advanced gastric cancer.
| Log-rank P-value | |||||
|---|---|---|---|---|---|
| Variables | n | mPFS (95% CI) | mOS (95% CI) | PFS | OS |
| Sex | 0.433 | 0.703 | |||
| Male | 56 | 5.0 (3.3–6.7) | 11 (9.6–12.4) | ||
| Female | 25 | 6.0 (3.6–8.4) | 12 (9.4–14.5) | ||
| Age, years | 0.773 | 0.898 | |||
| >60 | 33 | 5.5 (2.8–8.2) | 10.2 (6.0–14.4) | ||
| ≥60 | 48 | 6.0 (4.8–7.2) | 11.0 (10.0–12.0) | ||
| N stage | 0.590 | 0.081 | |||
| N1+N2 | 49 | 5.0 (3.6–6.4) | 11.6 (10.4–12.8) | ||
| N3 | 32 | 5.0 (2.8–7.2) | 10.2 (8.6–11.8) | ||
| TNM stage | 0.080 | 0.047a | |||
| I, II and III | 26 | 6.8 (5.9–7.7) | 12.0 (8.5–15.5) | ||
| IV | 55 | 4.5 (2.8–6.2) | 10.5 (8.5–12.5) | ||
| Tumor size, cm | 0.803 | 0.916 | |||
| >5 | 31 | 5.0 (2.9–7.1) | 11.0 (9.0–13.0) | ||
| ≥5 | 50 | 6.0 (4.4–7.6) | 11.0 (9.5–12.5) | ||
| Differentiation | 0.415 | 0.079 | |||
| Well to moderate | 27 | 6.0 (4.5–7.5) | 14.8 (8.0–21.6) | ||
| Poor | 54 | 4.5 (3.5–5.5) | 10.2 (8.2–12.2) | ||
| Platinum chemotherapy regimen | 0.025a | 0.359 | |||
| Platinum included | 38 | 6 (4.6–7.4) | 11.6 (9.3–13.9) | ||
| Non-platinum included | 43 | 4.5 (3.3–5.7) | 10.5 (9.0–12.0) | ||
| Paclitaxel chemotherapy regimen | 0.393 | 0.484 | |||
| Paclitaxel included | 39 | 4.4 (2.9–5.9) | 11.0 (7.1–14.9) | ||
| Non-paclitaxel included | 42 | 6 (4.6–7.4) | 11.0 (10.2–11.8) | ||
a
P<0.05. CI, confidence interval; OS, overall survival (months); mOS, median overall survival; PFS, progression-free survival (months); mPFS, median progression-free survival; TNM, Tumor-Node-Metastasis.